April 15 (Reuters) - Immunitybio Inc IBRX.O:
IMMUNITYBIO ANNOUNCES FDA SUBMISSIONS OF SUPPLEMENTAL BLA FOR NMIBC PAPILLARY DISEASE AND FOR EXPANDED ACCESS OF ANKTIVA® TO TREAT LYMPHOPENIA
IMMUNITYBIO ANNOUNCES FDA SUBMISSIONS OF SUPPLEMENTAL BLA FOR NMIBC PAPILLARY DISEASE AND FOR EXPANDED ACCESS OF ANKTIVA® TO TREAT LYMPHOPENIA